WCM
PVLA

Wedge Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Wedge Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,567
Closed -$1.76M – 641
2019
Q1 		$1.76M Buy
6,567
+1,254
+24% +$298K 0.02% 300
2018
Q4 		$1.13M Buy
5,313
+1,907
+56% +$592K 0.01% 321
2018
Q3 		$1.53M Hold
3,406
– – 0.01% 305
2018
Q2 		$1.38M Buy
3,406
+1,757
+107% +$836K 0.01% 317
2018
Q1 		$900K Buy
+1,649
New +$1.02M 0.01% 363

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Wedge Capital Management's PVLA Position: Q2 2019 in Review

Wedge Capital Management sold out of Palvella Therapeutics (PVLA) in Q2 2019, closing a stake of 6,567 shares — an estimated $1.76M sold.

Wedge Capital Management first reported a position in PVLA in Q1 2018 and held it in 5 quarters. The position peaked at $1.76M in Q1 2019. 93 funds tracked by Wall St. Rank hold PVLA as of Q2 2019.

  • Wedge Capital Management reported no remaining Palvella Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wedge Capital Management sold 6,567 Palvella Therapeutics shares in Q2 2019, an estimated $1.76M.
  • Wedge Capital Management first reported a position in Palvella Therapeutics in Q1 2018 and held it in 5 quarters.
  • Wedge Capital Management's Palvella Therapeutics position peaked at $1.76M in Q1 2019.
  • 93 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2019.

Based on Wedge Capital Management's 13F filing for Q2 2019, filed 1 Aug 2019.